Literature DB >> 21274557

No protective role for hypoxic pulmonary vasoconstriction in severe hypergravity-induced arterial hypoxemia.

Lars L Karlsson1, Malin Rohdin, Michael Nekludov, Malin Ax, Johan Petersson.   

Abstract

Supine subjects exposed to hypergravity show a marked arterial desaturation. Previous work from our laboratory has also shown a paradoxical reduction of lung perfusion in dependent lung regions in supine subjects exposed to hypergravity. We reasoned that the increased lung weight during hypergravity caused either direct compression of the blood vessels in the dependent lung tissue or that poor regional ventilation caused reduced perfusion through hypoxic pulmonary vasoconstriction (HPV). The objective of this study was to evaluate the importance of HPV through measurements of arterial oxygenation during exposure to hypergravity with normal and attenuated HPV. A further increased arterial desaturation during hypergravity with attenuated HPV would support the hypothesis that HPV contributes to the paradoxical redistribution of regional perfusion. In a two-phased randomized study we first exposed 12 healthy subjects to 5 G while supine during two single-blinded conditions; control and after 50 mg sildenafil p.o.. In a second phase, 12 supine subjects were exposed to 5 G during three single-blinded conditions; control, after 100 mg sildenafil p.o. and after inhalation of 10 μg iloprost. There was a substantial arterial desaturation by 5-30% units in all subjects with no or only minor differences between conditions. The results speak against HPV as a principal mechanism for the hypergravity-induced reduction of lung perfusion in dependent lung regions in supine humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21274557     DOI: 10.1007/s00421-010-1810-2

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  23 in total

1.  The external respiration and gas exchange in space missions.

Authors:  V M Baranov; M A Tikhonov; A N Kotov
Journal:  Acta Astronaut       Date:  1992-07       Impact factor: 2.413

Review 2.  Endothelin antagonism in pulmonary arterial hypertension.

Authors:  Stephen H Lee; Richard N Channick
Journal:  Semin Respir Crit Care Med       Date:  2005-08       Impact factor: 3.119

3.  Effect of lung volume on the distribution of pulmonary blood flow in man.

Authors:  J M Hughes; J B Glazier; J E Maloney; J B West
Journal:  Respir Physiol       Date:  1968-01

4.  Effects of sildenafil on hypoxic pulmonary vascular function in dogs.

Authors:  Pierre Fesler; Alberto Pagnamenta; Benoit Rondelet; François Kerbaul; Robert Naeije
Journal:  J Appl Physiol (1985)       Date:  2006-06-15

5.  Sildenafil inhibits hypoxia-induced pulmonary hypertension.

Authors:  L Zhao; N A Mason; N W Morrell; B Kojonazarov; A Sadykov; A Maripov; M M Mirrakhimov; A Aldashev; M R Wilkins
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

Review 6.  Pulse oximetry: applications and limitations.

Authors:  S J Barker; K K Tremper
Journal:  Int Anesthesiol Clin       Date:  1987

7.  Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia.

Authors:  Andrew R Hsu; Kimberly E Barnholt; Nicolas K Grundmann; Joseph H Lin; Stewart W McCallum; Anne L Friedlander
Journal:  J Appl Physiol (1985)       Date:  2006-02-02

Review 8.  Molecular mechanism of cGMP-mediated smooth muscle relaxation.

Authors:  J A Carvajal; A M Germain; J P Huidobro-Toro; C P Weiner
Journal:  J Cell Physiol       Date:  2000-09       Impact factor: 6.384

9.  Iloprost inhalation redistributes pulmonary perfusion and decreases arterial oxygenation in healthy volunteers.

Authors:  D Rimeika; A Sanchez-Crespo; S Nyren; S G E Lindahl; C U Wiklund
Journal:  Acta Anaesthesiol Scand       Date:  2009-07-22       Impact factor: 2.105

10.  Effects of sildenafil on exercise capacity in hypoxic normal subjects.

Authors:  Vitalie Faoro; Michel Lamotte; Gael Deboeck; Adriana Pavelescu; Sandrine Huez; Hervé Guenard; Jean-Benoît Martinot; Robert Naeije
Journal:  High Alt Med Biol       Date:  2007       Impact factor: 1.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.